Telix Pharma signs deals with two European pharma companies
Australia’s Telix Pharmaceuticals had a busy day, announcing a product development partnership with German company Therapeia as well as a collaboration with Atlab Pharma of France.
Telix will add Therapeia’s ACD-101 theranostic program for glioblastoma to its pipeline of advanced theranostic radiopharmaceutical products. Telix also has secured the option to acquire Therapeia under pre-agreed terms. The financial terms of the transaction are not disclosed.
Telix chief executive Chris Behrenbruch stated: “ACD-101 is a unique multi-action agent that has the potential to deliver something really new to the management of several very challenging malignancies, particularly glioblastoma. Early patient experience in Germany has demonstrated promising therapeutic results and we are excited to be working with the Therapeia team to take this program forward to Phase II and beyond.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze